CVS Health (NYSE:CVS) announced its quarterly earnings data on Wednesday. The pharmacy operator reported $1.84 EPS for the quarter, beating the Zacks’ consensus estimate of $1.77 by $0.07, Briefing.com reports. The firm had revenue of $64.81 billion during the quarter, compared to the consensus estimate of $62.99 billion. CVS Health had a net margin of 1.91% and a return on equity of 16.15%. The firm’s revenue was up 36.5% compared to the same quarter last year. During the same quarter last year, the firm earned $1.73 earnings per share. CVS Health updated its FY19 guidance to $6.97-7.05 EPS.
Shares of CVS traded up $0.69 during mid-day trading on Friday, reaching $72.47. 9,079,719 shares of the company’s stock were exchanged, compared to its average volume of 6,966,567. The company has a quick ratio of 0.64, a current ratio of 0.95 and a debt-to-equity ratio of 1.39. The company has a 50-day simple moving average of $64.66 and a two-hundred day simple moving average of $58.54. CVS Health has a 52-week low of $51.72 and a 52-week high of $82.15. The company has a market cap of $87.55 billion, a price-to-earnings ratio of 10.24, a PEG ratio of 1.46 and a beta of 0.86.
The firm also recently disclosed a quarterly dividend, which was paid on Monday, November 4th. Stockholders of record on Thursday, October 24th were paid a dividend of $0.50 per share. The ex-dividend date of this dividend was Wednesday, October 23rd. This represents a $2.00 dividend on an annualized basis and a dividend yield of 2.76%. CVS Health’s dividend payout ratio (DPR) is 28.25%.
A number of research firms have recently issued reports on CVS. Mizuho lifted their price target on shares of CVS Health from $71.00 to $82.00 and gave the company a “buy” rating in a research report on Friday. Citigroup lifted their price target on shares of CVS Health from $72.00 to $83.00 and gave the company a “buy” rating in a research report on Thursday. They noted that the move was a valuation call. Bank of America lifted their price target on shares of CVS Health from $72.00 to $75.00 and gave the company a “buy” rating in a research report on Thursday, September 12th. UBS Group reiterated a “buy” rating and set a $78.00 price target on shares of CVS Health in a research report on Thursday. Finally, Raymond James lifted their price target on shares of CVS Health from $75.00 to $80.00 and gave the company a “strong-buy” rating in a research report on Thursday. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $77.59.
CVS Health Company Profile
CVS Health Corporation provides health services and plans in the United States. Its Pharmacy Services segment offers pharmacy benefit management solutions, such as plan design and administration, formulary management, retail pharmacy network management, mail order pharmacy, specialty pharmacy and infusion, Medicare Part D, clinical, disease management, and medical spend management services.
Featured Story: What is the outlook for the FAANG stocks?
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.